STOCK TITAN

CBD Life Sciences Inc. (CBDL) Announces Open Market Share Buyback

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
buybacks

CBD Life Sciences (CBDL) has announced a significant financial restructuring, including a reduction of 3.5 billion authorized shares and the initiation of an open market share buyback program. The company has received Transfer Agent Approval for this share reduction, marking a strategic move to optimize its capital structure and enhance shareholder value.

The initiative aims to improve earnings per share, reduce dilution risks, and attract new investors. The company has highlighted recent achievements, including the launch of CBD Horse Paste and the approval of 3000MG Pain Relief Cream on Walmart Marketplace. CBDL also markets a mushroom supplement powder featuring reishi and lion's mane extracts.

According to President and CEO Lisa Nelson, these moves demonstrate the company's commitment to creating value for shareholders while establishing a foundation for future growth in the CBD and wellness markets.

CBD Life Sciences (CBDL) ha annunciato una significativa ristrutturazione finanziaria, inclusa una riduzione di 3,5 miliardi di azioni autorizzate e l'avvio di un programma di riacquisto di azioni sul mercato aperto. L'azienda ha ricevuto l'approvazione dell'agente di trasferimento per questa riduzione azionaria, segnando una mossa strategica per ottimizzare la propria struttura di capitale e aumentare il valore per gli azionisti.

L'iniziativa mira a migliorare gli utili per azione, ridurre i rischi di diluizione e attrarre nuovi investitori. L'azienda ha evidenziato recenti successi, inclusi il lancio della pasta per cavalli al CBD e l'approvazione della crema analgesica da 3000MG su Walmart Marketplace. CBDL commercializza anche una polvere di integratore a base di funghi contenente estratti di reishi e lion's mane.

Secondo la Presidente e CEO Lisa Nelson, queste manovre dimostrano l'impegno dell'azienda a creare valore per gli azionisti, stabilendo nel contempo una base per la futura crescita nei mercati del CBD e del benessere.

CBD Life Sciences (CBDL) ha anunciado una reestructuración financiera significativa, que incluye una reducción de 3.5 mil millones de acciones autorizadas y el inicio de un programa de recompra de acciones en el mercado abierto. La compañía ha recibido la aprobación del Agente de Transferencia para esta reducción de acciones, marcando un movimiento estratégico para optimizar su estructura de capital y aumentar el valor para los accionistas.

La iniciativa tiene como objetivo mejorar las ganancias por acción, reducir los riesgos de dilución y atraer nuevos inversores. La empresa destacó logros recientes, incluyendo el lanzamiento de Pasta de CBD para Caballos y la aprobación de la Crema para Alivio del Dolor de 3000MG en Walmart Marketplace. CBDL también comercializa un polvo de suplemento de hongos que presenta extractos de reishi y melena de león.

Según la Presidente y CEO Lisa Nelson, estos movimientos demuestran el compromiso de la empresa de crear valor para los accionistas mientras establece una base para el crecimiento futuro en los mercados de CBD y bienestar.

CBD Life Sciences (CBDL)는 35억 주의 허가된 주식을 감축하고 공개 시장에서의 자사주 매입 프로그램을 시작하는 등 중요한 재정 구조 조정을 발표했습니다. 이 회사는 자산 감소에 대한 양도 대리인 승인을 받아 자본 구조를 최적화하고 주주 가치를 향상시키기 위한 전략적 움직임을 보여줍니다.

이번 이니셔티브는 주당 수익을 개선하고 희석 위험을 줄이며 신규 투자자를 유치하는 것을 목표로 합니다. 이 회사는 최근 성과로 CBD 말용 페이스트 출시와 월마트 마켓플레이스에서 3000MG 진통 크림 승인 등을 강조했습니다. CBDL은 또한 영지 및 사자갈기 추출물이 포함된 버섯 보충제 가루를 판매하고 있습니다.

회장 겸 CEO인 리사 넬슨(Lisa Nelson)에 따르면, 이러한 조치는 주주 가치를 창출하려는 회사의 commitment을 보여주며, CBD 및 웰니스 시장에서의 미래 성장 기반을 마련하기 위한 것입니다.

CBD Life Sciences (CBDL) a annoncé une restructuration financière significative, incluant une réduction de 3,5 milliards d'actions autorisées et le lancement d'un programme de rachat d'actions sur le marché libre. L'entreprise a obtenu l'approbation de l'agent de transfert pour cette réduction d'actions, marquant un mouvement stratégique visant à optimiser sa structure de capital et à accroître la valeur pour les actionnaires.

Cette initiative vise à améliorer le bénéfice par action, à réduire les risques de dilution et à attirer de nouveaux investisseurs. L'entreprise a mis en avant ses récentes réalisations, y compris le lancement de la pâte pour chevaux au CBD et l'approbation d'une crème analgésique de 3000MG sur Walmart Marketplace. CBDL commercialise également une poudre de supplément à base de champignons contenant des extraits de reishi et de crinières de lion.

Selon la Présidente et CEO Lisa Nelson, ces mouvements démontrent l'engagement de l'entreprise à créer de la valeur pour les actionnaires tout en établissant une base pour la croissance future sur les marchés du CBD et du bien-être.

CBD Life Sciences (CBDL) hat eine bedeutende finanzielle Restrukturierung angekündigt, inklusive einer Reduzierung um 3,5 Milliarden genehmigte Aktien und der Einleitung eines Aktienrückkaufprogramms auf dem offenen Markt. Das Unternehmen hat die Genehmigung des Transferagenten für diese Aktienreduktion erhalten, was einen strategischen Schritt zur Optimierung der Kapitalstruktur und zur Erhöhung des Aktionärswerts darstellt.

Die Initiative zielt darauf ab, den Gewinn pro Aktie zu verbessern, das Risiko der Verwässerung zu reduzieren und neue Investoren anzuziehen. Das Unternehmen hat kürzlich erreichte Erfolge hervorgehoben, einschließlich der Einführung von CBD Horse Paste und der Genehmigung der 3000MG Schmerzcreme auf Walmart Marketplace. CBDL vertreibt auch ein Pilzpulver, das Extrakte aus Reishi und Löwenmähne enthält.

Laut Präsidentin und CEO Lisa Nelson zeigen diese Maßnahmen das Engagement des Unternehmens, Wert für die Aktionäre zu schaffen und gleichzeitig eine Grundlage für zukünftiges Wachstum in den CBD- und Wellness-Märkten zu schaffen.

Positive
  • Authorized share reduction of 3.5 billion shares, decreasing dilution risk
  • Implementation of open market share buyback program
  • Product expansion with CBD Horse Paste and 3000MG Pain Relief Cream on Walmart Marketplace
  • Strategic move to improve EPS and shareholder value
Negative
  • No specific details provided about buyback program size or timeline
  • No mention of financial resources allocated for share buyback

Company Reports 3.5 billion Share Reduction from the Authorization

SCOTTSDALE, AZ / ACCESS Newswire / January 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a trailblazer in the CBD and wellness industries, is proud to announce a transformative financial milestone-the successful reduction of its authorized share count by an extraordinary 3.5 billion shares, with Transfer Agent Approval. This reduction represents a monumental step forward in the company's ongoing commitment to optimizing its capital structure and delivering long-term value to shareholders.

An open market share buyback program has also been initiated, signaling a robust vote of confidence in CBDL's growth strategy and financial stability. This strategic decision to repurchase outstanding shares over time underscores the company's dedication to bolstering shareholder equity, while simultaneously streamlining the share pool to improve earnings per share and overall market appeal.

What Does This Mean for Shareholders?
The reduction of 3.5 billion authorized shares is an unprecedented move that marks a turning point for CBDL and its stakeholders. By significantly decreasing the authorized share count, CBDL enhances its financial health, reduces dilution risks, and sets the stage for a more attractive investment profile.

This development aligns with the company's broader mission of strengthening shareholder value through disciplined financial management. The open market buyback plan not only demonstrates confidence in the company's future growth but also creates opportunities to:

  • Improve Earnings Per Share (EPS): With fewer shares outstanding, future earnings will be distributed among a smaller pool of shareholders, enhancing per-share profitability.

  • Attract New Investors: A reduced share count coupled with a clear commitment to financial optimization makes CBDL a more compelling investment option for both retail and institutional investors.

  • Signal Market Confidence: Share buybacks often serve as a strong indicator that the company's leadership believes its stock is undervalued, signaling potential for future growth.

A Strategic Move in a Transformative Year
This announcement comes at a pivotal time for CBDL, as the company continues to expand its footprint in the rapidly evolving CBD market. CBDL has made headlines with its innovative product launches, including the groundbreaking CBD Horse Paste-a veterinarian-designed formulation that provides physical and psychological support for horses-and the recently approved 3000MG Pain Relief Cream now available on Walmart Marketplace. Additionally, CBDL's flagship mushroom supplement powder, featuring reishi and lion's mane extracts, has garnered significant attention for its proven benefits in reducing stress, enhancing cognitive performance, and supporting immune health. These achievements, coupled with the strategic share buyback initiative, position the company for sustainable growth and long-term profitability.

"Reducing our authorized shares by 3.5 billion and implementing an open market share buyback program represents a clear demonstration of our commitment to delivering value to our shareholders," said Lisa Nelson, President and CEO of CBD Life Sciences Inc. "This milestone reflects not only our confidence in the company's current trajectory but also our dedication to creating a solid foundation for future success."

The Road Ahead
CBDL's decision to embark on this transformative journey is rooted in its unwavering dedication to transparency, fiscal responsibility, and shareholder enrichment. The company's leadership is focused on leveraging its strong market position and innovative product portfolio to achieve sustained financial performance.

For shareholders and prospective investors, this news represents a significant opportunity to be part of CBDL's journey as it continues to redefine industry standards and deliver exceptional value. With a reduced share count and a clear roadmap for growth, CBDL is poised to make substantial strides in the CBD and wellness markets.

About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC PINK:CBDL) is an innovative company focused on the development and sale of high-quality CBD-based products. Through its commitment to research, innovation, and customer satisfaction, CBDL aims to enhance the health and wellness of its customers worldwide. With a diversified product line and strategic partnerships, the company continues to position itself as a leader in the dynamic CBD industry.

For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences Inc.



View the original press release on ACCESS Newswire

FAQ

How many authorized shares did CBDL reduce in January 2025?

CBDL reduced its authorized share count by 3.5 billion shares in January 2025, with Transfer Agent Approval.

What products has CBDL recently launched on Walmart Marketplace?

CBDL recently launched its 3000MG Pain Relief Cream on Walmart Marketplace.

What is the purpose of CBDL's share buyback program?

The share buyback program aims to improve earnings per share, reduce dilution risks, and demonstrate confidence in the company's growth strategy.

What new veterinary product has CBDL introduced?

CBDL has introduced CBD Horse Paste, a veterinarian-designed formulation for providing physical and psychological support for horses.

Who is currently serving as CBDL's President and CEO?

Lisa Nelson is currently serving as the President and CEO of CBD Life Sciences.

CBD LIFE SCIENCES INC

OTC:CBDL

CBDL Rankings

CBDL Latest News

CBDL Stock Data

1.25M
141.69M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Scottsdale